vs

Side-by-side financial comparison of Clearwater Paper Corp (CLW) and Indivior Pharmaceuticals, Inc. (INDV). Click either name above to swap in a different company.

Clearwater Paper Corp is the larger business by last-quarter revenue ($360.3M vs $357.0M, roughly 1.0× Indivior Pharmaceuticals, Inc.). Indivior Pharmaceuticals, Inc. runs the higher net margin — 28.9% vs -3.6%, a 32.4% gap on every dollar of revenue.

Clearwater Paper Corporation is an American pulp and paperboard manufacturer. The company was created on December 9, 2008, via a spin-off from Potlatch Corporation and is headquartered in Spokane, Washington.

Indivior is a global specialty pharmaceutical company dedicated to developing and commercializing evidence-based treatments for substance use disorders such as opioid use disorder and alcohol dependence, as well as related mental health conditions. Its primary operating markets are North America and Europe, with a portfolio of approved therapies targeting unmet medical needs for underserved patient groups.

CLW vs INDV — Head-to-Head

Bigger by revenue
CLW
CLW
1.0× larger
CLW
$360.3M
$357.0M
INDV
Higher net margin
INDV
INDV
32.4% more per $
INDV
28.9%
-3.6%
CLW

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CLW
CLW
INDV
INDV
Revenue
$360.3M
$357.0M
Net Profit
$-12.8M
$103.0M
Gross Margin
-0.2%
82.1%
Operating Margin
22.7%
Net Margin
-3.6%
28.9%
Revenue YoY
-4.7%
Net Profit YoY
-103.2%
390.5%
EPS (diluted)
$0.79

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLW
CLW
INDV
INDV
Q1 26
$360.3M
Q4 25
$386.4M
$357.0M
Q3 25
$399.0M
$314.0M
Q2 25
$391.8M
$302.0M
Q1 25
$378.2M
$266.0M
Q4 24
$387.1M
Q3 24
$393.3M
$307.0M
Q2 24
$344.4M
$299.0M
Net Profit
CLW
CLW
INDV
INDV
Q1 26
$-12.8M
Q4 25
$38.3M
$103.0M
Q3 25
$-53.3M
$42.0M
Q2 25
$2.7M
$18.0M
Q1 25
$-6.3M
$47.0M
Q4 24
$199.1M
Q3 24
$5.8M
$22.0M
Q2 24
$-25.8M
$-97.0M
Gross Margin
CLW
CLW
INDV
INDV
Q1 26
-0.2%
Q4 25
4.5%
82.1%
Q3 25
4.7%
73.2%
Q2 25
11.0%
82.8%
Q1 25
9.7%
83.1%
Q4 24
3.8%
Q3 24
7.7%
78.5%
Q2 24
-0.6%
73.6%
Operating Margin
CLW
CLW
INDV
INDV
Q1 26
Q4 25
1.9%
22.7%
Q3 25
-13.9%
13.7%
Q2 25
2.5%
23.8%
Q1 25
-1.1%
24.8%
Q4 24
-4.0%
Q3 24
-0.3%
11.4%
Q2 24
-13.6%
-39.5%
Net Margin
CLW
CLW
INDV
INDV
Q1 26
-3.6%
Q4 25
9.9%
28.9%
Q3 25
-13.4%
13.4%
Q2 25
0.7%
6.0%
Q1 25
-1.7%
17.7%
Q4 24
51.4%
Q3 24
1.5%
7.2%
Q2 24
-7.5%
-32.4%
EPS (diluted)
CLW
CLW
INDV
INDV
Q1 26
Q4 25
$2.36
$0.79
Q3 25
$-3.30
$0.33
Q2 25
$0.17
$0.14
Q1 25
$-0.38
$0.38
Q4 24
$11.87
Q3 24
$0.35
$0.16
Q2 24
$-1.55
$-0.72

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLW
CLW
INDV
INDV
Cash + ST InvestmentsLiquidity on hand
$36.5M
$195.0M
Total DebtLower is stronger
$361.1M
Stockholders' EquityBook value
$813.8M
$-98.0M
Total Assets
$1.6B
$1.2B
Debt / EquityLower = less leverage
0.44×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLW
CLW
INDV
INDV
Q1 26
$36.5M
Q4 25
$30.7M
$195.0M
Q3 25
$34.4M
$445.0M
Q2 25
$46.7M
$510.0M
Q1 25
$44.0M
$373.0M
Q4 24
$79.6M
Q3 24
$35.5M
Q2 24
$39.6M
Total Debt
CLW
CLW
INDV
INDV
Q1 26
$361.1M
Q4 25
$346.8M
Q3 25
$337.0M
Q2 25
$330.1M
Q1 25
Q4 24
$283.4M
Q3 24
$1.2B
Q2 24
$1.1B
Stockholders' Equity
CLW
CLW
INDV
INDV
Q1 26
$813.8M
Q4 25
$825.3M
$-98.0M
Q3 25
$783.0M
$-207.0M
Q2 25
$836.8M
$-257.0M
Q1 25
$836.6M
$-285.0M
Q4 24
$854.6M
Q3 24
$664.6M
$-310.0M
Q2 24
$658.6M
$-281.0M
Total Assets
CLW
CLW
INDV
INDV
Q1 26
$1.6B
Q4 25
$1.6B
$1.2B
Q3 25
$1.6B
$1.4B
Q2 25
$1.6B
$1.5B
Q1 25
$1.6B
$1.4B
Q4 24
$1.7B
Q3 24
$2.5B
Q2 24
$2.5B
Debt / Equity
CLW
CLW
INDV
INDV
Q1 26
0.44×
Q4 25
0.42×
Q3 25
0.43×
Q2 25
0.39×
Q1 25
Q4 24
0.33×
Q3 24
1.73×
Q2 24
1.74×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLW
CLW
INDV
INDV
Operating Cash FlowLast quarter
$-221.0M
Free Cash FlowOCF − Capex
$-245.0M
FCF MarginFCF / Revenue
-68.6%
Capex IntensityCapex / Revenue
6.7%
Cash ConversionOCF / Net Profit
-2.15×
TTM Free Cash FlowTrailing 4 quarters
$-93.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLW
CLW
INDV
INDV
Q1 26
Q4 25
$5.0M
$-221.0M
Q3 25
$34.0M
$-39.0M
Q2 25
$-28.2M
$158.0M
Q1 25
$1.5M
$75.0M
Q4 24
$-35.1M
Q3 24
$16.2M
$2.0M
Q2 24
$21.1M
$88.0M
Free Cash Flow
CLW
CLW
INDV
INDV
Q1 26
Q4 25
$-9.9M
$-245.0M
Q3 25
$15.7M
$-59.0M
Q2 25
$-51.1M
$141.0M
Q1 25
$-31.2M
$70.0M
Q4 24
$-68.1M
Q3 24
$-30.8M
$-5.0M
Q2 24
$3.0M
$84.0M
FCF Margin
CLW
CLW
INDV
INDV
Q1 26
Q4 25
-2.6%
-68.6%
Q3 25
3.9%
-18.8%
Q2 25
-13.0%
46.7%
Q1 25
-8.2%
26.3%
Q4 24
-17.6%
Q3 24
-7.8%
-1.6%
Q2 24
0.9%
28.1%
Capex Intensity
CLW
CLW
INDV
INDV
Q1 26
Q4 25
3.9%
6.7%
Q3 25
4.6%
6.4%
Q2 25
5.8%
5.6%
Q1 25
8.6%
1.9%
Q4 24
8.5%
Q3 24
12.0%
2.3%
Q2 24
5.3%
1.3%
Cash Conversion
CLW
CLW
INDV
INDV
Q1 26
Q4 25
0.13×
-2.15×
Q3 25
-0.93×
Q2 25
-10.44×
8.78×
Q1 25
1.60×
Q4 24
-0.18×
Q3 24
2.79×
0.09×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLW
CLW

Segment breakdown not available.

INDV
INDV

Sublocade$233.0M65%
Sublingual And Other$69.0M19%
Other$49.0M14%
Perseris$6.0M2%

Related Comparisons